Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Opioid treatment programs in the Clinical Trials Network: representativeness and buprenorphine adoption.

Ducharme LJ, Roman PM.

J Subst Abuse Treat. 2009 Jul;37(1):90-4. doi: 10.1016/j.jsat.2008.09.003. Epub 2008 Nov 11.

2.

Innovation adoption in substance abuse treatment: exposure, trialability, and the Clinical Trials Network.

Ducharme LJ, Knudsen HK, Roman PM, Johnson JA.

J Subst Abuse Treat. 2007 Jun;32(4):321-9. Epub 2007 Feb 22.

3.

Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network.

Knudsen HK, Abraham AJ, Johnson JA, Roman PM.

J Subst Abuse Treat. 2009 Oct;37(3):307-12. doi: 10.1016/j.jsat.2008.12.004. Epub 2009 Jul 3.

4.

From research to the real world: buprenorphine in the decade of the Clinical Trials Network.

Ling W, Jacobs P, Hillhouse M, Hasson A, Thomas C, Freese T, Sparenborg S, McCarty D, Weiss R, Saxon A, Cohen A, Straus M, Brigham G, Liu D, McLaughlin P, Tai B.

J Subst Abuse Treat. 2010 Jun;38 Suppl 1:S53-60. doi: 10.1016/j.jsat.2010.01.009.

5.

Low Rates of Adoption and Implementation of Rapid HIV Testing in Substance Use Disorder Treatment Programs.

Frimpong JA, D'Aunno T, Helleringer S, Metsch LR.

J Subst Abuse Treat. 2016 Apr;63:46-53. doi: 10.1016/j.jsat.2015.12.001. Epub 2015 Dec 28.

6.

Adoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programs.

Andrews CM, D'Aunno TA, Pollack HA, Friedmann PD.

Med Care Res Rev. 2014 Feb;71(1):43-60. doi: 10.1177/1077558713503188. Epub 2013 Sep 18.

7.

Impact of research network participation on the adoption of buprenorphine for substance abuse treatment.

Rieckmann TR, Abraham AJ, Kovas AE, McFarland BH, Roman PM.

Addict Behav. 2014 May;39(5):889-96. doi: 10.1016/j.addbeh.2014.01.016. Epub 2014 Feb 7.

8.

Timing of buprenorphine adoption by privately funded substance abuse treatment programs: the role of institutional and resource-based interorganizational linkages.

Savage SA, Abraham AJ, Knudsen HK, Rothrauff TC, Roman PM.

J Subst Abuse Treat. 2012 Jan;42(1):16-24. doi: 10.1016/j.jsat.2011.06.009. Epub 2011 Aug 9.

9.

Testing use of payers to facilitate evidence-based practice adoption: protocol for a cluster-randomized trial.

Molfenter T, Kim JS, Quanbeck A, Patel-Porter T, Starr S, McCarty D.

Implement Sci. 2013 May 10;8:50. doi: 10.1186/1748-5908-8-50.

10.

Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs.

Friedmann PD, Jiang L, Alexander JA.

J Behav Health Serv Res. 2010 Jul;37(3):322-37. doi: 10.1007/s11414-009-9169-z. Epub 2009 Mar 19.

11.

A longitudinal study of organizational formation, innovation adoption, and dissemination activities within the National Drug Abuse Treatment Clinical Trials Network.

Roman PM, Abraham AJ, Rothrauff TC, Knudsen HK.

J Subst Abuse Treat. 2010 Jun;38 Suppl 1:S44-52. doi: 10.1016/j.jsat.2009.12.008.

12.

Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.

Amass L, Ling W, Freese TE, Reiber C, Annon JJ, Cohen AJ, McCarty D, Reid MS, Brown LS, Clark C, Ziedonis DM, Krejci J, Stine S, Winhusen T, Brigham G, Babcock D, Muir JA, Buchan BJ, Horton T.

Am J Addict. 2004;13 Suppl 1:S42-66.

13.

Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability.

Koch AL, Arfken CL, Schuster CR.

Drug Alcohol Depend. 2006 Jul 27;83(3):274-8. Epub 2006 Jan 18.

PMID:
16413146
14.

Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence.

Ridge G, Gossop M, Lintzeris N, Witton J, Strang J.

J Subst Abuse Treat. 2009 Jul;37(1):95-100. doi: 10.1016/j.jsat.2008.09.007. Epub 2008 Nov 11.

PMID:
19004598
15.

Improving treatment for opioid dependence: a perspective from the Ohio Valley node of the NIDA Clinical Trials Network.

Winstanley EL, Brigham GS, Babcock D, Winhusen T.

Prog Community Health Partnersh. 2014 Spring;8(1):99-107. doi: 10.1353/cpr.2014.0002.

16.

Substance abuse treatment organizations as mediators of social policy: slowing the adoption of a congressionally approved medication.

Wallack SS, Thomas CP, Martin TC, Chilingerian J, Reif S.

J Behav Health Serv Res. 2010 Jan;37(1):64-78. doi: 10.1007/s11414-008-9132-4. Epub 2008 Jul 31.

PMID:
18668369
17.

Office-based buprenorphine treatment for opioid-dependent patients.

McCance-Katz EF.

Harv Rev Psychiatry. 2004 Nov-Dec;12(6):321-38. Review.

PMID:
15764468
18.

Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial.

Back SE, Payne RL, Wahlquist AH, Carter RE, Stroud Z, Haynes L, Hillhouse M, Brady KT, Ling W.

Am J Drug Alcohol Abuse. 2011 Sep;37(5):313-23. doi: 10.3109/00952990.2011.596982.

19.

State policy influence on the early diffusion of buprenorphine in community treatment programs.

Ducharme LJ, Abraham AJ.

Subst Abuse Treat Prev Policy. 2008 Jun 20;3:17. doi: 10.1186/1747-597X-3-17.

20.

Buprenorphine and addiction: challenges for the pharmacist.

Boatwright DE.

J Am Pharm Assoc (Wash). 2002 May-Jun;42(3):432-8.

PMID:
12030630

Supplemental Content

Support Center